Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

166 ritonavir * RTV

12th World AIDS Conference

Keyword

Abstract

-Keyword

Abstract

ning indinavir (IDV) with
saquinavir compared to
avir in combination with
), didanosine (ddl) and
iretroviral treatment of
artments/The impact of
minary results/Effect of
se to saquinavir (SQV)/

(RTV): Results from first study/N 22372
/saquinavir in protease inhibitor ( 22391
and double nucleoside inhibitor t 22395
as a triple therapy in antiretroviral 22401
in combination with zidovudine (Z 22409
/saquinavir/stavudine on viral loa 23397
(RTV)/saquinavir(SQV) versus R 32197
(RTV) therapy in patients who ha 229*/32287

BA and Quantiplex HIV
arative analysis of HIV
able estimates of HIV-1
rate of decline of HIV-1
SQV) determine HIV-1
hanol ingestion on HIV
on therapy with a HIV-1
itative detection of viral
onitoring plasma HIV-1
or adherence and HIV-1
ansient increase in viral
cells to number of viral
IDV failure: Results on

assays for quantification of HIV-1 in c
and TNF-a/Predicting clinical progre
undetectability and log reduction in cli
in plasma correlates with nelfinavir co
response over a 48-week period/Pla
levels and CD4 counts in HIV positive
< 400 cps/ml/Switch from indinavir (I
of HIV-1 subtypes by a PCR and a bra
levels/The use of NASBA for monitori
response/Protease inhibitor adheren
level/Emergence of syncytium-induci
copies in sera of anergic patients with
viral load and CD4 T cells count/Qua

42177
42188
42204
510*/42259
511*/42261
60159
60181
60230
60306
60363
60568
60721
60966

atients on a saquinavir/ therapy/Pre-existent mutations o
d with a combination of and saquinavir (ANRS 069 pilot s
Salvage therapy using /saquinavir with a non-nucleoside
-reported adherence to /saquinavir (RTV/SQV) and ritona
c interactions between (RTV), nelfinavir (NFV), and the n
of efavirenz (EFV) and (RIT) after multiple oral doses in
tis; cross-reactivity with /Indinavir-induced urticaria and le
ne/Interaction between and levothyroxine/Interaction bet
QV) in combination with (RTV) and d4T in patients with ad
f school girls in Makoko Riverine Community, Nigeria/Integrated a
oms at red-light areas ( RLAs ) through community participation an
ne (NVP) and rifampin ( RMP )/Pharmacokinetic (PK) interaction b
leocapsid protein, viral RNA and protease of HIV-1 on infectious vi
nfection/HIV-1 cellular load arise in late stage of HIV-diseas
ysis of full-length HIV-1 genomic sequences in the genital tra
ACTG 175/HIV serum, CD4 cell numbers and risk for clinical
omes/Detection of HIV in plasma below quantifiable limits as
LV) plasma levels, HIV responses and DLV resistance durin: Suppression of HIV-1 to fewer than 50 copies/ml during 5 m
rotease inhibitors/HIV load in blood and seminal plasma of p
ions between CD4 and response in antiretroviral-naive patie
an, C6te d'lvoire/HIV-1 plasma viral load and CD4 counts bef
alaria illness and HIV-1 viral burden/The association betwee
knowing plasma HIV-1 level?/Is cell-associated infectious HI
ildren/Pattern of HIV-1 load from birth to school-age in perina
ific differences in HIV-1 level in a longitudinal study of HIV-1 s
count and plasma HIV copy number/Fas mediated apoptosi
Relationship with HIV-1, TNF-related molecules and clinical o
orrelation between HIV and levels of cytokines, chemokines
andida and plasma HIV in asymptomatic patients with HIV inf
/Relationship of HIV-1 copies in plasma and CD4 counts to h
ween seminal plasma (SP-RNA) and blood plasma RNA (B
ory of undetectable HIV induced by combination antiretroviral
0 to 500/pl and plasma < 5000 copies ml during HAART (AZ
B-Thai/HIV-1 subtype levels in semen of HIV-1 infected Tha
on (GTI)/HIV DNA and detection in cervicovaginal (CV) secr
ort Study (MACS)/HIV, CD4+ cell count, and immune activat
ncreased plasma HIV /Increased resting energy expenditur
al/Change in log1o HIV and protease inhibitor use associated
nfected patients/HIV-1, as measured by the Gen-Probe TMA
sorder/Change in CSF level correlates with the effects of ma
erebrospinal fluid HIV-1 levels and efavirenz concentrations i
cal strategy trial of HIV antiretroviral (ARV) monitoring/Self r
nter evaluation of HIV-1 levels in dried plasma and whole bloo
tance where no CD4 or monitoring is available in Brazil/Antir
ens quantitative HIV-1 PCR assay in persons infected with H
th quantiplex v2.0 HIV assay and the nuclisens for quantitati
itive detection of HIV-1 of diverse origins, including type O str
es/Highly sensitive HIV quantitation from plasma, peripheral
y-based study of HIV-2 load in pregnant women attending he
oviral DNA and plasma changes in advanced patients after 6
ion to quantitate HIV-1 from different genetic subtypes/Effici
uantification of plasma for non-B HIV-1 subtypes using the H
ing of sera for HIV viral: Feasibility for diagnosis of acute prim
ted mothers, Thailand/ and DNA PCR for early diagnosis of i
nd/Evaluation of HIV-1 assays for diagnosis and quantitation
e men and women/HIV in oral washes of Senegalese men an
men/The course of HIV levels over 17 years of HIV infection i
ce in determining HIV-1 levels present in CDC performance e
T-PCR) on plasma HIV decay/Effect of processing delay, ant
d/Cervicovaginal HIV-1 levels and plasma viral load/Cervicov
m study of HIV and HCV levels in haemophiliacs (Grehco Stud
enance of stable HIV-1 in HIV-1 infection prior to AIDS/CD4+
/Impact of plasma HIV on CD4 change and outcome for wo
rtality/The roles of HIV levels and CD4 counts when assessi
onitor assays for HIV-1 quantitation/Comparison of NucliSen
to the variability of HIV measurements in serially collected cli
ntitative assay for HIV-1 using branched DNA technology/Per
SF) versus plasma HIV levels in patients with AIDS-related n
e and quantitative PCR assays in HIV-1 infected children/Cor
ssays/Plasma HIV-1 quantification: Comparative evaluatio
on and relationship with levels in plasma/HIV-1 cellular infecti

32294
32302
32308
32362
42265
42269
60274
60571
60714
33370
33426
60623
379*/11131
11158
11169
507*/12124
12128
12206
12275
12284
12363
13271
13297
13308
13361
13379
21165
21173
21178
22214
22317
22339
22377
22383
23395
23450
506*/32167
32168
32180
32195
32198
32202
32379
33166
33167
41127
41128
343*/41129
41133
165*/41135
41140
41145
41154
42105
166*/42106
42124
42135
42140
42142
42144
42148
42151
42152
42153
42159
42162
42163
42168
42170
42171
42175
42176

rotocol/Linear range of Roche Amplicor HIV-1 Monitor assay usin 41146
on of the ultra sensitive Amplicor HIV-1 MonitorTM assay/M 42143
arison of NucliSens and Monitor assays for HIV-1 RNA qua 42162
ildren with HIV/AIDS in Romania /Zidovudine plus zalcitabine com 12263
ted with HIV infection in /Mucocutaneous manifestations 32274
Os in India, Caribbean,, Ukraine and Russia/Partnershi 34331
affected by HIV/AIDS in /A model of care for children and 34339
HIV/AIDS in Constanta, /The reducing of personal and so 43156
on of HIV-1 subtypes in /Serologic and phylogenetic cha 60172
e experience of the PSI/ social marketing program/Innov 60705
cutaneous infections in Romanian HIV infected children: Medical 32266
g with HIV children: The experience/Doctors and volunt 60610
s/Harm reduction in the Romany community in Vilnius/Harm redu 33396
atients departments in Rome, Italy/Prescriptions of protease inhi 22396
of a reference center in /HIV infection among transsexual se 570*/23534
ars of harm reduction in /The effects of two years of harm red 577*/33391
HIV reference center in /HIV infection among individuals fro 60257
ssexual sex workers in /HIV infection and related behaviour 60258
n metropolitan area of /Characteristics of AIDS patients ref 60439
m USAC, Abidjan/The Rorschach test and AIDS: Study of the Ro 24156
1 genotypes circulate in Rosario, Argentina/At least four HIV-1 ge 13175

n/Population inquire in about the general knowledge in HI
a poor neighborhood of, Argentina/HIV testing and couns
ic hospital in the City of (Province of Santa Fe, Argentina)
ming AIDS prevention:,1997-6years of experience/Tra
nd a police academy in /Comparing sexual behaviour and
ttended in an NGO in, 1995-1997/Prevalence of HIV in
rovincial hospitals from City, Argentina/Systematization
he Police Academy in /Sexual activity and knowledge on
ions/Popular survey in about attitudes toward HIV/AIDS i
without treatment from, Argentina/Correlation between v
ravenous drug users in Rostov-on-Don, South Russia/The total p
Performance of a rapid RPR method for syphilis screening of ante
ospective partner trials ( RPT ) HIV vaccine study design for measur
e reductase inhibitors ( RRIs ) in the murine model of immunodefici
women in Porto Alegre, RS State, Brazil/Seroreactivity to HIV-1 pe
a "rapid screening tool ( RST )" to determine eligibility for HIV clinica
yncytial virus infection ( RSV ): A case report/Delayed detection of
ith nelfinavir and two RT-inhibitors in previously untreated HIV-i
a mRNA by competitive RT-PCR in PBMC of HIV-infected patients/
lasma/A competitive method for the quantitation of HIV
ulant and assay (bDNA, ) on plasma HIV RNA decay/Effec
y an in-house nested and measurement of the drug resi
V-1 subtypes (B or E) by /A simple method for the identifica
onal?/Fitness of HIV-1 RT mutants: Is MOller's ratchet operational
hat confer resistance to inhibitors among drug naive HIV-positiv
/Mutation pattern of the and protease genes in HIV-infected chil
udies on MKC-442 with inhibitors in long-term culture of HIV-1-i
e of the nonnucleoside inhibitor (+)-calanolide A/Combination
endent development of inhibitor (RTI) resistance patterns in cer
reverse transcriptase ( ) gene and its predictive value at the star
t reverse transcription ( )-linked polymerase chain reaction (PC
reverse transcriptase ( ) shows increased sensitivity to adefovir
tion of mutations in the gene of HIV-1/A comparison of sequen
notypic changes in HIV which develop during PreveonTM (adefo
nce mutations in HIV-1 /Line Probe assay compared with clona
ations of the LiPA HIV-1 mutation detection assay/Novel clinical
nnogenetics Lipa HIV-1 assay/Semi-quantitative HIV-1 mutatio
t reverse transcription ( )-linked polymerase chain reaction (PC
ay/Analysis of the HIV resistance profile of patients receiving
detection by LiPA HIV1-: A useful tool for therapeutic choices?/
nd child health (RCH - RTI /STD/HIV/AIDS) package that facilitate
opment of RT inhibitor ( ) resistance patterns in cerebrospinal fl
transcriptase inhibitor ( ) concentrations in human plasma/Met
ductive tract infections ( RTIs ) and sexually transmitted diseases (S
uced doses of ritonavir ( RTV ) plus saquinavir (SQV) in the treatme
/Treatment of ritonavir ( )/saquinavir (SQV) versus RTV/SQV/s

14200
33330
42458
43200
43399
43466
43541
60096
60928
60991
33420
33241
43549
12356
11202
42247
60597
12256
21181
41136
42144
42179
60229
11157
11168
12257
12362
12366
563*/32284
32311
41139
41214
41216
41218
41219
41223
41225
42134
60854
60968
13575
563*/32284
42277
23381
12114
291*/12274